Abstract Search

ea0063gp58 | Acromegaly and GH | ECE2019

ACROSTUDY – safety and efficacy in a cohort of 110 Naïve patients with acromegaly treated with pegvisomant

Wajnrajch Michael , Gomez Roy , Hey-Hadavi Judith , Kelepouris Nikoletta , van der Lans Joli , Loftus Jane , Camacho-Hubner Cecilia , Fleseriu Maria , Salvatori Roberto , Cara Jose , Palladino Andrew

Background: ACROSTUDY is an open-label, non-interventional post-authorization safety study that began in 2004 to evaluate safety in at least 1000 acromegaly patients treated with the GH receptor antagonist pegvisomant (PEGV). This commitment was fulfilled in Jan 2013. ACROSTUDY was later amended to enroll an additional 110 patients that were naïve/semi-naive to PEGV treatment. Semi-naïve patients are defined as not having received PEGV therapy for at least 6 months p...

0 shares

ea0049ep1046 | Pituitary - Clinical | ECE2017

Heterogeneity of the patient pathway for adult growth hormone deficiency: Perspectives from a CEE Endocrinologists expert panel

Shimon Ilan , Badiu Corin , Bossowski Artur , Doknic Mirjana , Dzivite-Krisane Iveta , Hana Vaclav , Kollerova Jana , Natchev Natchev Emil , Pfeifer Marija , SzŨcs Nikolette , Hey-Hadavi Juliana , Gomez Roy

Introduction: Effective identification, diagnosis and management of growth hormone (GH) deficiency in adults are crucial for treating endocrinologists to provide the best in patient care. As such, it is important that we share our experiences to understand challenges and obstacles to enhance the patient journey. The objective of this project was to start identifying these challenges and obstacles.Methods and findings: In November 2016, an expert panel of...

0 shares

Endocrine Abstracts

ACROSTUDY – safety and efficacy in a cohort of 110 Naïve patients with acromegaly treated with pegvisomant

Heterogeneity of the patient pathway for adult growth hormone deficiency: Perspectives from a CEE Endocrinologists expert panel

BiosciAbstracts